Use of dha, epa or dha-derived epa for treating a pathology associated with cellular oxidative damage

Abstract

The present invention relates to the use of an acid enriched in docosahexaenoic acid (DHA) or eicosapentaenoic acid (EPA) or DHA-derived EPA for manufacturing a drug for the treatment of processes that involve associated oxidative damage. In particular, it is for the treatment of processes associated with neurodegenerative, ocular, ischaemic and inflammatory pathology, atherosclerosis, with oxidative damage to DNA and with physical exercise.

1 . (canceled) 
     
     
         2 . A method of treating cellular ageing or inhibiting premature senescence in human skin, the method comprising administering docosahexaenoic acid (DHA) to the human skin, wherein the DHA is incorporated into a glyceride, and wherein a portion of the DHA is incorporated into an sn-2 position of the glyceride. 
     
     
         3 . The method of  claim 2 , wherein the cellular ageing or premature senescence is associated with cellular damage evidenced by a shortening of DNA telomeres in cells of the human skin. 
     
     
         4 . The method of  claim 2 , wherein the glyceride is a triglyceride and between 40 and 100% by weight of fatty acids in the triglyceride is the DHA. 
     
     
         5 . The method of  claim 2 , wherein the glyceride is a triglyceride and between 66 and 100% by weight of fatty acids in the triglyceride is the DHA. 
     
     
         6 . The method of  claim 2 , wherein the DHA is enzymatically incorporated into the glyceride. 
     
     
         7 . The method of  claim 2 , wherein the glyceride is formulated in a cosmetic application. 
     
     
         8 . The method of  claim 7 , wherein the cosmetic application is in the form of an emulsion. 
     
     
         9 . The method of  claim 1 , wherein the DHA is administered topically to the skin.